2013
20P NCI 8609: Multicenter Phase I Trial of PARP Inhibitor Veliparib with Carboplatin in Advanced Breast Cancer
Ramaswamy B, Geyer S, Lustberg M, Wesolowski R, Andreopoulou E, Knopp M, Villalona M, Chen A, Grever M, Shapiro C. 20P NCI 8609: Multicenter Phase I Trial of PARP Inhibitor Veliparib with Carboplatin in Advanced Breast Cancer. Annals Of Oncology 2013, 24: iii19. DOI: 10.1093/annonc/mdt081.1.Peer-Reviewed Original Research
2010
Phase II trial of neoadjuvant chemotherapy (NCT) with weekly nanoparticle albumin-bound paclitaxel (Nab-P), carboplatin (CBP), and bevacizumab (BEV) in women with clinical stages II-III breast cancer (BC): Pathologic response prediction by changes in angiogenic volume (AV) by dynamic contrast magnetic resonance imaging (DCE-MRI).
Mrozek E, Lustberg M, Knopp M, Spigos D, Yang X, Houton L, Ramaswamy B, Layman R, Povoski S, Agnese D. Phase II trial of neoadjuvant chemotherapy (NCT) with weekly nanoparticle albumin-bound paclitaxel (Nab-P), carboplatin (CBP), and bevacizumab (BEV) in women with clinical stages II-III breast cancer (BC): Pathologic response prediction by changes in angiogenic volume (AV) by dynamic contrast magnetic resonance imaging (DCE-MRI). Journal Of Clinical Oncology 2010, 28: 604-604. DOI: 10.1200/jco.2010.28.15_suppl.604.Peer-Reviewed Original ResearchNeoadjuvant chemotherapyBreast cancerDynamic contrast magnetic resonance imagingWeekly nanoparticle albumin-bound paclitaxelNanoparticle albumin-bound paclitaxelClinical stage IIPhase II trialAlbumin-bound paclitaxelContrast magnetic resonance imagingMagnetic resonance imagingII trialResonance imagingStage IIBevacizumabCarboplatinChemotherapyCancerPaclitaxelTrials
2009
Biomodulation of capecitabine by weekly paclitaxel and carboplatin in patients with advanced solid tumor malignancies: A dose-escalating phase I study
Lustberg M, Nuovo J, Thomas J, Monk P, Kim S, Villalona-Calero M, Bekaii-Saab T. Biomodulation of capecitabine by weekly paclitaxel and carboplatin in patients with advanced solid tumor malignancies: A dose-escalating phase I study. Journal Of Clinical Oncology 2009, 27: 2569-2569. DOI: 10.1200/jco.2009.27.15_suppl.2569.Peer-Reviewed Original ResearchDay 1Common grade 3/4 toxicitiesCapecitabine-based treatmentGrade 3/4 toxicitiesAdvanced solid tumorsExpression of TPThymidine phosphorylase activityAUC 6Carboplatin doseWeekly paclitaxelNeutropenic feverPrior therapyTherapeutic indexCapecitabineDose levelsSolid tumorsDay 8Dihydropyrimidine dehydrogenaseCarboplatinMalignant tissuesPhase IPaclitaxelNeutropeniaPatientsPhosphorylase activity